Niraj R. Chavan

Niraj R. Chavan

Auto-generated profile, based on publicly available information

Niraj R. Chavan

Department of Obstetrics and Gynecology University of Kentucky College of Medicine Lexington KY USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2018 in European Journal of Obstetrics & Gynecology and Reproductive Biology
Verified
Journal Article
Closed access
CWCorrine M. Williams
Corrine M. Williams
IAIbitola Asaolu
Ibitola Asaolu
NCNiraj R. Chavan
Niraj R. Chavan
LWLucy H. Williamson
Lucy H. Williamson
ALAlysha M. Lewis
Alysha M. Lewis
KAKristin B. Ashford
Kristin B. Ashford

22 November 2018 in Experimental Physiology
Verified
Journal Article
Open access
PDF file
LRLeryn J. Reynolds
Leryn J. Reynolds
NCNiraj R. Chavan
Niraj R. Chavan
LDLogan B. DeHoff
Logan B. DeHoff
JPJoshua Preston
Joshua Preston
HMHannah F. Maddox
Hannah F. Maddox
KPKevin J. Pearson
Kevin J. Pearson
New Findings: What is the central question of this study? Is chemerin, an adipokine implicated in obesity, increased in neonates following in utero cigarette smoke exposure. What is the main finding and its importance? Chemerin mRNA expression was increased and chemerin DNA methylation was decreased in babies born to mothers who smoked during pregnancy. These data provide a potential mechanism that may be mediating the increased obesity risk in individuals that are born to mothers who smoked during pregnancy. It has been shown that in utero tobacco exposure increases offspring risk for obesity, but the mechanisms responsible for this increased risk are not well understood. Chemerin is an adipokine that regulates adipocyte differentiation. This chemokine is elevated in obese individuals and with smoke exposure, but its levels have not been measured in neonates exposed to cigarette smoke in utero. We examined chemerin gene expression [n = 31 non‐smoker (NS) and 15 smoker (S)] and DNA methylation (n = 28 NS and n = 11 S) in skin collected from babies born to mothers who smoked during pregnancy as compared to non‐smoking controls. Quality RNA and DNA were isolated from foreskin tissue following circumcision, and chemerin gene expression and DNA methylation were assessed. Further, in a second cohort, we utilized primary dermal foreskin fibroblasts as a functional measure of adipogenesis in living cells (n = 11 NS and n = 8 S). Cells were stimulated with an adipogenic cocktail, mRNA was isolated from cells after 14 days, and chemerin gene expression assessed via real‐time PCR. Chemerin mRNA was elevated in both whole tissue (NS: 2409.20 ± 555.28 counts and S: 2966.72 ± 636.84 counts; P < 0.01) and primary fibroblasts (NS: 1.12 ± and S: 2.13 ± ; P = 0.04) collected from infants born to smoking mothers. Chemerin DNA methylation was reduced in whole tissue of offspring born to smokers (NS: 4.18 ± 1.28 and S: 3.07 ± 1.31%; P = 0.02), which may contribute to the increased gene expression. Neonates born to mothers who smoke during pregnancy exhibit distinct changes in chemerin gene expression in response to in utero tobacco smoke exposure which are regulated in part by epigenetic alterations.

1 May 2017 in Obstetrics & Gynecology
Verified
Journal Article
Closed access
PDF file
MLMegan Lawlor
Megan Lawlor
KMKristen McQuerry
Kristen McQuerry
NCNiraj Chavan
Niraj Chavan
LSLori Shook
Lori Shook
ACAgatha Critchfield
Agatha Critchfield
Neonatal Opioid Withdrawal Syndrome (NOWS) is a significant public health problem. Care-By-Parent (CBP) is a model for mothers to room-in with their opioid-exposed infants during inpatient observation for postnatal development of NOWS. The purpose of this study is to determine if CBP is associated with a reduction in treatment-requiring NOWS. We performed a retrospective, case control study of pregnant women enrolled in a combined prenatal and medication assisted treatment (MAT) program for opioid-dependent patients. Patients stable on MAT (as indicated by appropriate urine drug screen at Labor & Delivery admission) who participated in CBP were matched by gestational age, smoking and breastfeeding status with controls also stable in the combined prenatal/MAT program. Fisher Exact Test, ANOVA and logistic regression were performed. Primary outcome was diagnosis of treatment-requiring NOWS in neonates. Forty women met inclusion criteria (20 cases, 20 controls). There were no differences in age, gravidity, parity, birth weight, Apgar scores, or buprenorphine dose (P>.05). For the primary outcome, there was a statistically significant reduction in the rate of treatment requiring NOWS among cases vs controls (OR 0.08 95% CI 0.01-0.71). Significant difference was noted in patient time in program (cases vs controls, 19 vs 14 weeks, P=0.02) however, logistic regression demonstrated that the time in program did not affect the rate of NOWS (OR 0.99 95% CI 0.88-1.12). CBP significantly reduces the rate of treatment requiring NOWS. This approach decreases NICU admissions, increases maternal-child bonding and has the potential for alleviating maternal substance abuse patterns.